Möchten Sie immer auf dem neuesten Stand bleiben?

POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada...

INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...

SOFIA, Bulgaria, May 04, 2022 (GLOBE NEWSWIRE) -- ZigiWave announced today that Maria Zasheva has been appointed as the new CEO of the company. As a dedicated and hands-on business leader, Maria...

Customers can convert points accrued from purchases to hard dollar amounts via an electronic gift card through this new integration. ShinyBud Cannabis Co. is the first to launch to loyalty...

Dubai, UAE, April 27, 2022 (GLOBE NEWSWIRE) -- RFOX, the fast-growing metaverse company building the future of the Internet, launched the RFOX VALT metaverse’s minimum viable product (MVP) today to...

POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...

NEW YORK, April 14, 2022 (GLOBE NEWSWIRE) -- Invisible, unphishable multi-factor authentication (MFA) provider Beyond Identity today announced integrations with additional single sign-on (SSO)...

POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for...

TROY, Mich., April 04, 2022 (GLOBE NEWSWIRE) -- Independent specialty pharmacy DirectRx announced today the launch and implementation of DirectFlow technology, designed to streamline the process of...

Santa Clara, CA, March 30, 2022 (GLOBE NEWSWIRE) -- More than ever, the ability to quickly innovate new digital products and services is critical to enterprise strategies for market differentiation,...